Avocet AvoSure PT
This article was originally published in The Gray Sheet
Executive Summary
System for consumer prothrombin time self-testing gains FDA clearance, announced Dec. 16. The hand-held meter, which will be launched in mid-January at a list price of approximately $750, reads a disposable reagent strip that requires a drop of blood. Avocet received its first FDA clearance in 1998 to market AvoSure PT Pro+ for physician point-of-care use
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.